Symbols

DCPH(Delisted)

Deciphera·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 2

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About DCPH

Deciphera Pharmaceuticals, Inc.

A biopharmaceutical company that developing new medicines for cancer

Industry

Established Date

Listing Date

09/28/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

355

Fiscal Year Ends

12-31

Website

www.deciphera.com

Security Type

Common stock

Office address

200 Smith Street, Waltham, MA, 02451

Business

Introduction

Deciphera Pharmaceuticals, Inc., is a biopharmaceutical company focused on discovering, developing and delivering important new drugs to patients to treat cancer. The company is leveraging its proprietary switch controlled kinase inhibitor platform and deep expertise in kinase biology to execute their strategy to develop a broad portfolio of innovative drugs. The company has an approved drug, Qin Rock, which is developed through their proprietary platform. In addition to Qin Luo, the company is developing three clinical-stage drug candidates and advancing its research-stage projects. The Company fully owns Qin Rock and all its drug candidates, with the exception of Qin Rock's development and commercialization license agreement in Greater China. The Company is preparing to launch QINLOCK in Europe, and the Company has entered into and intends to enter into selected reseller agreements in the future to offer QINLOCK in regions where the Company does not plan to distribute QINLOCK on its own (e.g. Australia and Canada).

Company Financials

EPS

DCPH has released its 2024 Q1 earnings. EPS was reported at -0.54, versus the expected -0.55, beating expectations. The chart below visualizes how DCPH has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

DCPH has released its 2024 Q1 earnings report, with revenue of 45.00M, reflecting a YoY change of 34.55%, and net profit of -45.08M, showing a YoY change of 9.12%. The Sankey diagram below clearly presents DCPH's revenue sources and cost distribution.